Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Documenti analoghi

• Reply
  di: Spencer I. Danto, et al.
  Pubblicazione: (2025)
• Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
  di: Christina Charles‐Schoeman, et al.
  Pubblicazione: (2024)
• Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial
  di: Kristina Lend, et al.
  Pubblicazione: (2024)
• The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease
  di: Rebecca T. Brooks, et al.
  Pubblicazione: (2024)
• Air Pollution's Hidden Toll: Risks for Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Lung Disease
  di: Sofia Ajeganova, et al.
  Pubblicazione: (2025)